Physician profile
Donald Savitz
NPI 1407849912
$25,855.28
in general payments reported to CMS, 2019-2025
34 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,319 · 2020: $7,266 · 2021: $1,630 · 2022: $1,965 · 2023: $2,036 · 2024: $2,595 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,195 · Education: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,194.91 |
| Education | $480.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $7,688.38 | 2019-2025 | |
| Almirall LLC | $6,054.36 | 2019-2024 | Klisyri |
| Abbvie INC. | $1,881.75 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Genzyme Corporation | $1,652.17 | 2019-2025 | |
| Janssen Biotech, INC. | $1,583.42 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,195.17 | 2019-2025 | Dupixent |
| Incyte Corporation | $803.02 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $701.99 | 2019-2025 | Nemluvio, Aklief |
| Ucb, INC. | $663.81 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $557.63 | 2019-2024 | Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $482.86 | 2019-2025 | |
| Lilly USA, LLC | $396.75 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $346.11 | 2019-2024 | Otezla, Enbrel |
| Dermavant Sciences, INC. | $304.48 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $244.07 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $222.07 | 2019-2025 | Adbry, Anzupgo |
| Vyne Pharmaceuticals INC. | $175.37 | 2020 | |
| Sanofi-Aventis U.S. LLC | $158.39 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $153.90 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $114.50 | 2019-2025 | Siliq, Targretin, Cabtreo |
| Revance Therapeutics, INC. | $99.57 | 2024 | Daxxify |
| Arcutis Biotherapeutics, INC. | $70.12 | 2023-2024 | Zoryve |
| Sebela Pharmaceuticals INC. | $53.17 | 2021-2022 | |
| Epi Health, LLC | $37.72 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $33.28 | 2019 | |
| Aclaris Therapeutics, INC. | $29.92 | 2019 | |
| Journey Medical Corporation | $25.88 | 2020-2021 | |
| Organon LLC | $24.64 | 2025 | Vtama |
| Dermira, INC. | $22.84 | 2020 | |
| Mylan Pharmaceuticals INC. | $20.51 | 2019 | |
| Merck Sharp & Dohme LLC | $16.98 | 2019 | |
| Mission Pharmacal Company | $15.30 | 2020 | |
| Allergan, INC. | $13.34 | 2021 | |
| Nabriva Therapeutics, Plc | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Savitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.